Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.51 |
| ▸ | MEN1 | O00255 | 7/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | HPGD | P15428 | 5/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.51 |
| ▸ | PRNP | P04156 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.49 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CLK1 | P49759 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7397793 | 0.86 | ALDH1A1 (0.44) | XDHKMT2AALDH1A1POLB | |
| SCHEMBL7398696 | 0.85 | DYRK1B (0.47) | XDHMAPTALDH1A1GAACLK1 | |
| SCHEMBL7392189 | 0.85 | CNR1 (0.51) | XDHKMT2AMEN1KDM4EGAA | |
| SCHEMBL7368321 | 0.85 | NPC1 (0.50) | SMN1; SMN2KMT2AMEN1KDM4EMAPT | |
| SCHEMBL7365549 | 0.85 | TSHR (0.45) | KDM4ECA12CA1CA2TSHR | |
| SCHEMBL7403582 | 0.85 | RAB9A (0.47) | SMN1; SMN2L3MBTL1KMT2AMEN1KDM4E | |
| SCHEMBL7399753 | 0.85 | RAB9A (0.46) | SMN1; SMN2HTTKMT2AMEN1KDM4E | |
| SCHEMBL7396486 | 0.83 | ROCK2 (0.58) | SMN1; SMN2HTTKMT2AMEN1MAPT | |
| SCHEMBL7399852 | 0.82 | KIT (0.46) | MAPK1 | |
| SCHEMBL7366309 | 0.82 | NPC1 (0.48) | XDHSMN1; SMN2HTTL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562602-A2 | IMMEDIATE RELEASE TOPICAL PHARMACEUTICAL FORMULATION FOR ENHANCEMENT OF FEMALE SEXUAL DESIRE AND RESPONSIVENESS | Vivus, Inc. (US) | 2005-08-17 | — | — | EP | claimed |
| WO-2004037262-A2 | IMMEDIATE RELEASE TOPICAL PHARMACEUTICAL FORMULATION FOR ENHANCEMENT OF FEMALE SEXUAL DESIRE AND RESPONSIVENESS | VIVUS, INC. (US) | 2004-05-06 | — | — | WO | claimed |
| US-20040014761-A1 | Treatment of female sexual dysfunction with phosphodiesterase inhibitors | VIVUS, INC. | 2004-01-22 | — | — | US | claimed |
| US-5728563-A | Cyclic nucleotide phosphodiesterase and a method for production thereof | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1998-03-17 | — | — | US | claimed |
| EP-0682109-A1 | CYCLIC NUCLEOTIDASE AND PROCESS FOR PRODUCING THE SAME | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1995-11-15 | — | — | EP | claimed |
| US-4657906-A | CARDIOVASCULAR DISORDERS | SMITH KLINE & FRENCH LABORATORIES LTD. (GB) | 1987-04-14 | — | — | US | claimed |
| US-4556711-A | CARDIOTONIC AGENTS | SMITH KLINE & FRENCH LABORATORIES LTD. (US) | 1985-12-03 | — | — | US | claimed |
| EP-0096517-A2 | Aryl pyrazinones | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1983-12-21 | — | — | EP | claimed |
| EP-2218442-A1 | Methods, compositions, and kits for the treatment of ophthalmic disorders | CombinatoRx, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| EP-1956906-A2 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF MEDICAL CONDITIONS | CombinatoRx, Incorporated (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20070225217-A1 | Methods, compositions, and kits for the treatment of medical conditions | COMBINATORX, INCORPORATED (US) | 2007-09-27 | — | — | US | disclosed |
| WO-2007056457-A2 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF MEDICAL CONDITIONS | COMBINATORX, INCORPORATED (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20040044080-A1 | Treatment of dyspareunia with topically administered nitroglycerin formulations | VIVUS, INC. | 2004-03-04 | — | — | US | disclosed |
| US-6469016-B1 | VAGINAL, VULVAR AND/OR URETHRAL ADMINISTRATION OF A PHARMACEUTICAL FORMULATION CONTAINING A VASOACTIVE AGENT TO INCREASE VAGINAL LUBRICATION | VIVUS, INC. | 2002-10-22 | — | — | US | disclosed |
| US-4657906-A | CARDIOVASCULAR DISORDERS | SMITH KLINE & FRENCH LABORATORIES LTD. (GB) | 1987-04-14 | — | — | US | disclosed |
| US-4657906-A | CARDIOVASCULAR DISORDERS | SMITH KLINE & FRENCH LABORATORIES LTD. (GB) | 1987-04-14 | — | — | US | disclosed |
| US-4556711-A | CARDIOTONIC AGENTS | SMITH KLINE & FRENCH LABORATORIES LTD. (US) | 1985-12-03 | — | — | US | disclosed |
| US-4556711-A | CARDIOTONIC AGENTS | SMITH KLINE & FRENCH LABORATORIES LTD. (US) | 1985-12-03 | — | — | US | disclosed |
| US-4514568-A | 5-(4-Nitrophenyl)-2(1H)-pyrazinones | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-04-30 | — | — | US | disclosed |
| EP-0096517-A2 | Aryl pyrazinones | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1983-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225217-A1 | Methods, compositions, and kits for the treatment of medical conditions | TNF, PYGM, IL6 | XDH 2726/4885SMN1; SMN2 2527/4885HTT 2206/4885 |
| US-20040014761-A1 | Treatment of female sexual dysfunction with phosphodiesterase inhibitors | PDE3A, PDE3B, PDE12 | XDH 206/4885SMN1; SMN2 2165/4885HTT 4688/4885 |
| US-20040044080-A1 | Treatment of dyspareunia with topically administered nitroglycerin formulations | PDE12, PDE3A, PDE2A | XDH 2153/4885SMN1; SMN2 2982/4885HTT 4625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.